| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing M Imielinski, AH Berger, PS Hammerman, B Hernandez, TJ Pugh, ... Cell 150 (6), 1107-1120, 2012 | 1978 | 2012 |
| Comprehensive genomic profiles of small cell lung cancer J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ... Nature 524 (7563), 47-53, 2015 | 1965 | 2015 |
| First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised … YY Janjigian, K Shitara, M Moehler, M Garrido, P Salman, L Shen, ... The Lancet 398 (10294), 27-40, 2021 | 1571 | 2021 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1461 | 2012 |
| High-throughput oncogene mutation profiling in human cancer RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ... Nature genetics 39 (3), 347-351, 2007 | 1160 | 2007 |
| Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer RJ Kelly, JA Ajani, J Kuzdzal, T Zander, E Van Cutsem, G Piessen, ... New England Journal of Medicine 384 (13), 1191-1203, 2021 | 1029 | 2021 |
| Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010 | 1007 | 2010 |
| PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR ML Sos, M Koker, BA Weir, S Heynck, R Rabinovsky, T Zander, ... Cancer research 69 (8), 3256-3261, 2009 | 652 | 2009 |
| Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, ... Cancer discovery 1 (1), 78-89, 2011 | 582 | 2011 |
| Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation HB Salvesen, SL Carter, M Mannelqvist, A Dutt, G Getz, IM Stefansson, ... Proceedings of the National Academy of Sciences 106 (12), 4834-4839, 2009 | 352 | 2009 |
| Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions ML Sos, K Michel, T Zander, J Weiss, P Frommolt, M Peifer, D Li, R Ullrich, ... The Journal of clinical investigation 119 (6), 1727-1740, 2009 | 323 | 2009 |
| Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer ML Sos, S Fischer, R Ullrich, M Peifer, JM Heuckmann, M Koker, ... Proceedings of the National Academy of Sciences 106 (43), 18351-18356, 2009 | 296 | 2009 |
| Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids L Fernandez-Cuesta, M Peifer, X Lu, R Sun, L Ozretić, D Seidel, T Zander, ... Nature communications 5 (1), 3518, 2014 | 291 | 2014 |
| Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors J George, V Walter, M Peifer, LB Alexandrov, D Seidel, F Leenders, ... Nature communications 9 (1), 1048, 2018 | 285 | 2018 |
| CD74–NRG1 Fusions in Lung Adenocarcinoma L Fernandez-Cuesta, D Plenker, H Osada, R Sun, R Menon, F Leenders, ... Cancer discovery 4 (4), 415-422, 2014 | 278 | 2014 |
| Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of … S Debey, U Schoenbeck, M Hellmich, BS Gathof, R Pillai, T Zander, ... The pharmacogenomics journal 4 (3), 193-207, 2004 | 257 | 2004 |
| PD-L1 expression in small cell neuroendocrine carcinomas AM Schultheis, AH Scheel, L Ozretić, J George, RK Thomas, T Hagemann, ... European Journal of Cancer 51 (3), 421-426, 2015 | 256 | 2015 |
| Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer K Shitara, JA Ajani, M Moehler, M Garrido, C Gallardo, L Shen, ... Nature 603 (7903), 942-948, 2022 | 217 | 2022 |
| Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18) F] fluorodeoxyglucose and [(18) F] fluorothymidine positron … T Zander, M Scheffler, L Nogova, C Kobe, W Engel-Riedel, M Hellmich, ... J Clin Oncol 29 (13), 1701-1708, 2011 | 202 | 2011 |
| Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ T Zander, JA Kraus, C Grommes, U Schlegel, D Feinstein, T Klockgether, ... Journal of neurochemistry 81 (5), 1052-1060, 2002 | 192 | 2002 |
